United Therapeutics Corporation (UTHR) Share buybacks
- Total buybacks · last 12 months (USD): Value $2.50B; Formula and calculation Trailing-year cash paid for share repurchases. Period ending 2026-06-30..
- Buyback yield · 12 months: Value (m); Formula and calculation Cash paid for share repurchases / current market cap. Period ending 2026-06-30..
Share buybacks
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total buybacks · last 12 months (USD) | $2.50B | Trailing-year cash paid for share repurchases. Period ending 2026-06-30. |
| Buyback yield · 12 months | (m) | Cash paid for share repurchases / current market cap. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Buybacks · 12 months | 2.50B USD | Payments for Repurchase of Common Stock |
| Market cap | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total buybacks | Market cap (USD) | Buyback yield |
|---|---|---|---|
| 2026-06-30 | $2.50B | (m) | (m) |
| 2026-03-31 | $2.50B | (m) | (m) |
| 2025-12-31 | $1.00B | (m) | (m) |
| 2025-09-30 | $1.00B | (m) | (m) |
| 2025-06-30 | $0.00 | (m) | (m) |
| 2025-03-31 | $0.00 | (m) | (m) |
| 2024-12-31 | $1.00B | (m) | (m) |
| 2024-09-30 | (m) | (m) | (m) |
| 2024-06-30 | (m) | (m) | (m) |
| 2024-03-31 | (m) | (m) | (m) |
| 2023-12-31 | $0.00 | (m) | (m) |
| 2023-09-30 | (m) | (m) | (m) |
| 2023-06-30 | (m) | (m) | (m) |
| 2023-03-31 | (m) | (m) | (m) |
| 2022-12-31 | $0.00 | (m) | (m) |
| 2017-12-31 | $250.00M | (m) | (m) |
| 2017-09-30 | $354.50M | (m) | (m) |
| 2017-06-30 | $490.30M | (m) | (m) |
| 2016-12-31 | $500.00M | (m) | (m) |
| 2016-09-30 | $395.48M | (m) | (m) |
| 2016-06-30 | $317.38M | (m) | (m) |
| 2016-03-31 | $365.38M | (m) | (m) |
| 2015-12-31 | $394.48M | (m) | (m) |
| 2015-09-30 | $474.40M | (m) | (m) |
| 2015-06-30 | $442.35M | (m) | (m) |
| 2015-03-31 | $537.73M | (m) | (m) |
| 2014-12-31 | $483.08M | (m) | (m) |
| 2014-09-30 | $403.16M | (m) | (m) |
| 2014-06-30 | $377.56M | (m) | (m) |
| 2014-03-31 | $134.17M | (m) | (m) |
| 2013-12-31 | $42.44M | (m) | (m) |
| 2013-09-30 | $99.51M | (m) | (m) |
| 2013-06-30 | $142.44M | (m) | (m) |
| 2013-03-31 | (m) | (m) | (m) |
| 2012-12-31 | $188.00M | (m) | (m) |
| 2012-09-30 | (m) | (m) | (m) |
| 2012-06-30 | (m) | (m) | (m) |
| 2011-12-31 | $212.00M | (m) | (m) |
| 2011-10-31 | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |